Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 23, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging test using a special form of iodine called iodine-124 to help doctors see how well cancer cells in patients with metastatic thyroid cancer absorb radioactive iodine. The goal is to find out if this test can accurately measure the amount of iodine taken up by the cancer. If the test shows that the cancer is absorbing enough iodine, patients will continue with their usual treatment. However, if it shows low absorption, doctors may consider switching to a different type of therapy.

To participate in this trial, patients must be adults diagnosed with thyroid cancer that has spread to other parts of the body. They should have already had their thyroid gland removed and must have measurable disease confirmed by recent imaging tests like ultrasounds or scans. The trial is currently recruiting participants aged 18 and older, and it is important to note that pregnant women cannot take part. Participants can expect to undergo this new imaging test and, based on the results, their doctor will decide the best course of treatment moving forward.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults with thyroid carcinoma confirmed by pathology.
• • Adult thyroid carcinoma patients who have undergone total thyroidectomy
• • Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care.
• • The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present.
• • All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning.
• Exclusion Criteria:
• • Age less than 18 years.
• • Patients who are pregnant.